candidemia
candidemia
Explore linked clinical trials. Standard reference: MONDO:00440704 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis. | Bacterial Infections and Mycoses, Fungemia, Infections, Inflammation, Invasive Fungal Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Sepsis, Systemic Inflammatory Response Syndrome, Torulopsis, candidemia, candidiasis, candidiasis, invasive, fungal infectious disease | Recruiting | Phase 3 | 2026-09-14 | NCT05421858 | |
| Shortening Treatment Duration in Uncomplicated Candidemia: the CanTEN Trial | Bacterial Infections and Mycoses, Fungemia, Infections, Inflammation, Invasive Fungal Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Sepsis, Systemic Inflammatory Response Syndrome, candidemia, candidiasis, candidiasis, invasive, fungal infectious disease | Not yet recruiting | Phase 4 | 2026-09-01 | NCT07788586 | |
| A Study Comparing Short-course Antifungal Therapy (SCAT) 7 Day vs Standard 14 Day Antifungal Therapy for Uncomplicated Candidemia | Bacterial Infections and Mycoses, Fungemia, Infections, Inflammation, Invasive Fungal Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Sepsis, Systemic Inflammatory Response Syndrome, candidemia, candidiasis, candidiasis, invasive, fungal infectious disease | Not yet recruiting | Not stated | 2025-04-04 | NCT06907992 | |
| A Randomized Study of a Short Duration Therapy for Candidemia | Bacterial Infections and Mycoses, Fungemia, Infections, Inflammation, Invasive Fungal Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Sepsis, Systemic Inflammatory Response Syndrome, candidemia, candidiasis, candidiasis, invasive, fungal infectious disease | Not yet recruiting | Phase 3 | 2025-03-05 | NCT06859671 |